



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07D 253/06, A61K 31/53, C07D 403/10, 417/10	A1	(11) International Publication Number: WO 99/02504 (43) International Publication Date: 21 January 1999 (21.01.99)
(21) International Application Number: PCT/EP98/04192 (22) International Filing Date: 2 July 1998 (02.07.98) (30) Priority Data: 97202117.4 10 July 1997 (10.07.97) EP (71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). (72) Inventors; and (75) Inventors/Applicants (for US only): FREYNE, Eddy, Jean, Edgard [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). BOECKX, Gustaaf, Maria [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). VAN WAUWE, Jean, Pierre, Frans [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). DIELS, Gaston, Stanislas, Marcella [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>

(54) Title: 6-AZAUACIL DERIVATIVES AS IL-5 INHIBITORS**(57) Abstract**

The present invention is concerned with the use of compounds of formula (I): the *N*-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein *p* represents 0, 1, 2 or 3; *q* represents 0, 1, 2, 3 or 4; *R*¹ represents hydrogen, C₁-alkyl, mono- or di(C₁-alkyl)amino, C₁-alkyloxy, mercapto, C₁-alkylthio, C₃-cycloalkyl, aryl or C₁-alkyl substituted with mono- or di(C₁-alkyl)-amino, C₁-alkyloxy, aryl or Het; *R*² represents cyano or a radical of formula -C(=X)-Y-R³; wherein X represents O or S; Y represents O, S, NR⁶ or a direct bond; *R*⁵ represents hydrogen; C₃-cycloalkyl; aryl or optionally substituted C₁-alkyl; and where Y is a direct bond, *R*⁵ may also be halo or Het; *R*³ and *R*⁴ each independently represents halo, haloC₁-alkyl, C₁-alkyl, hydroxy, C₁-alkyloxy, C₁-alkylcarbonyloxy, mercapto, C₁-alkylthio, C₁-alkylsulfonyl, C₁-alkylsulfinyl, haloC₁-alkylsulfonyl, aryl, cyano, nitro, amino, mono- and di(C₁-alkyl)amino or (C₁-alkylcarbonyl)amino; aryl represents phenyl or substituted phenyl; and Het represents an optionally substituted heterocycle; in the manufacture of a medicament useful for treating eosinophil-dependent inflammatory diseases. The invention also relates to novel compounds, their preparation and compositions comprising them.

